BETAGAN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Jun 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETAGAN is an ophthalmic solution (eye drops) approved in 1989 for the treatment of glaucoma and ocular hypertension. The drug is a small-molecule beta-blocker formulated for topical ocular administration. It reduces intraocular pressure by decreasing aqueous humor production.
LOE Approaching
Brand faces moderate competitive pressure (30/100) with LOE approaching, likely requiring defensive commercial strategies and right-sizing of team resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BETAGAN offers stable but limited career upside given its mature lifecycle stage and approaching loss of exclusivity. Roles are primarily commercial/defensive in nature, suited for professionals managing portfolio optimization rather than launch or growth acceleration.
Brand ManagerAccount Manager
Worked on BETAGAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.